# Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas

> **NCT01298401** · PHASE1 · COMPLETED · sponsor: **Radiation Therapy Oncology Group** · enrollment: 8 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** ganitumab
- **DRUG:** capecitabine
- **DRUG:** gemcitabine hydrochloride
- **RADIATION:** 3-dimensional conformal radiation therapy

## Key facts

- **NCT ID:** NCT01298401
- **Lead sponsor:** Radiation Therapy Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2015-11-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01298401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01298401, "Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01298401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*